Cochlear share price lower on acquisition update

Cochlear has moved a step closer to making a new acquistion.

| More on:
A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price is edging lower today.

In morning trade, the hearing solutions company's shares are down 1% to $234.

Why is the Cochlear share price falling?

This weakness follows the release of an update on the company's proposed acquisition of Oticon Medical.

According to the release, the UK Competition and Markets Authority (CMA) has approved Cochlear's acquisition of Oticon Medical, Demant's hearing implants business.

In its report, the CMA concluded that Cochlear's acquisition of Oticon Medical's cochlear implants business (CI business) does not raise competition concerns and is permitted to proceed.

However, this does not include Oticon Medical's bone conduction implants business. This may explain the weakness in the Cochlear share price today.

The release reveals that the CMA concluded that Cochlear's acquisition would result in a substantial lessening of competition in the UK and has prohibited the acquisition of that part of the Oticon Medical business.

Commenting on the bone conduction implants business, Cochlear's CEO & President, Dig Howitt, said

We were disappointed to be blocked from acquiring the acoustics business. We will still be able to offer Cochlear's technology to those customers into the future as our Baha sound processors are already compatible with Oticon Medical's Ponto acoustic implants.

Cochlear and Demant will now pursue a transfer of Oticon Medical's CI business at a zero headline purchase price, the completion of which will ensure that Cochlear can provide ongoing support for Oticon Medical's current base of around 20,000 cochlear implant recipients. Howitt adds:

We look forward to welcoming Oticon Medical's cochlear implant customers to the Cochlear family. We will work closely with Demant to ensure a seamless transition, with continued access to current Oticon Medical technology for customers in the coming years. We plan to develop and commercialise next generation sound processors and services that will enable customers to transition to and benefit from Cochlear's technology platform over time.

What impact will the business have?

Oticon Medical's CI business is expected to add around $10 million to annual revenue. And while the business is currently loss-making, Cochlear is working on a plan that returns the business to sustainable profitability as quickly as possible.

In addition, integration costs, which include the development of compatible next generation sound processors, are yet to be determined. However, they are currently estimated to be $30 million to $60 million. Cochlear continues to target a long-term net profit margin of 18%.

It is worth noting that the transaction remains conditional on the satisfaction of customary closing conditions and receipt of other competition approvals from the Australian Competition and Consumer Commission and the European Commission.

If all goes to plan, the transaction is expected to close by December.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »